Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

Press releases published on June 1, 2026

Jun. 1, 2026

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

Indeterminate GlobeNewswire

Jun. 1, 2026

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Indeterminate GlobeNewswire

Jun. 1, 2026

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

Indeterminate GlobeNewswire

Jun. 1, 2026

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

Indeterminate GlobeNewswire

Jun. 1, 2026

Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster

Indeterminate GlobeNewswire

Jun. 1, 2026

Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis

Indeterminate GlobeNewswire

Jun. 1, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Jun. 1, 2026

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

Indeterminate GlobeNewswire

Jun. 1, 2026

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Indeterminate GlobeNewswire

Jun. 1, 2026

Spectral AI Announces Voting Results of Annual Meeting of Stockholders

Indeterminate GlobeNewswire

Jun. 1, 2026

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

Indeterminate GlobeNewswire

Jun. 1, 2026

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

Indeterminate GlobeNewswire

Jun. 1, 2026

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Indeterminate GlobeNewswire

Jun. 1, 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Indeterminate GlobeNewswire

Jun. 1, 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Indeterminate GlobeNewswire